Bellomo et al. [1] confirm the clinical [2‐4] data showing a reduction in noradrenaline (NA) requirements in the setting of septic shock following administration of an alpha-2 agonist, dexmedetomidine.
The intensivist is unaware that the retrospective analysis has thoroughly changed the design of the study from “sedation vs. outcome” to “sympathetic de-activation vs. circulation” (i.e., upregulation of alpha-1 receptors vs. NA requirements). Furthermore, the design is not optimal. SPICE III [5] compared early dexmedetomidine (“dex”) versus usual sedation (− 2 < RASS < + 1) [5]. Bellomo achieved RASS ~ − 4, in both groups (results [1]): The dex group received also propofol (95% of the patients), midazolam (43%) and higher doses of opioids (Table S1 [1]). Thus, any effect of dex is drowned as a consequence of adding usual sedation to dex. Nevertheless, in the dex group, (a) the overall NA requirement (“NA equivalent”) is lowered by 25%, nonsignificantly, but of daily clinical relevance for the intensivist; (b) the NA requirement necessary to achieve a target pressure is lowered, as a function of dose (i.e., compatible with a dose-dependent sympathetic de-activation). NA requirements should be readdressed in the dexmedetomidine-only patients versus the usual sedation-only patients, throughout the whole SPICE III [5] database.
Anzeige
Authors’ response
Luca Cioccari3, 4 and Rinaldo Bellomo4, 5
(3)
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
(4)
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Prahran, VIC, 3004, Australia
(5)
Centre for Integrated Critical Care, The University of Melbourne, Melbourne, Australia
We thank Dargent and colleagues for the comments about our study on the hemodynamic changes seen in patients with septic shock treated with dexmedetomidine as primary sedating agent versus usual care [1]. We agree that the retrospective nature of the study creates problems because the original study was a sedation trial with mortality as the outcome, while the retrospective investigation of the hemodynamic effects of dexmedetomidine was a post hoc physiological assessment in patients who were mostly deeply sedated at the time of investigation (median RASS of − 3) and receiving propofol in most cases, fentanyl in the majority and midazolam in close to half of cases. In such a setting, the effect of dexmedetomidine is markedly attenuated by the impact of these drugs. Thus, we agree that it is all the more remarkable that, in the dexmedetomidine group, the overall norepinephrine (noradrenaline) requirements were lower and that the dose required to achieve target mean arterial pressure was also decreased. Finally, we agree that comparing patients on dexmedetomidine only versus patients receiving usual care would be ideal. Unfortunately, we were unable to identify such a cohort of patients. Nonetheless, within the limitations of the design and the population studied, we think that our findings are consistent with a substantial body of experimental data supporting the view that, in the septic, vasodilated state, dexmedetomidine (and central alpha-2 agonists) infusion does not exacerbate hypotension or increase vasopressor requirements but, in fact, appears to do the opposite [6‐9].
Acknowledgements
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Anzeige
Competing interests
LQ received honoraria and unrestricted research grants from Boehringer-Ingelheim, France, UCB Pharma, Belgium, and Abbott International, Il, USA [1986–1996], and holds US patent 8 846 606 B2, September 30, 2014 (method and drug composition for treating septic shock hypotension).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.